Fig. 1From: Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionationa Estimated biochemical failure-free survival (BCFFS) of the original five different dose schedules. b Estimated BCFFS after separation into the moderate hypofractionation (MHF) group with a fractional dose < 5 Gy and extreme hypofractionation (EHF) group with a fractional dose ≥5 GyBack to article page